Cargando…

A rapid and quantitative reversed-phase HPLC-DAD/ELSD method for lipids involved in nanoparticle formulations

Lipid nanoparticles (LNPs) have shown great success as drug delivery systems, especially for mRNA vaccines, as those developed during the Covid-19 pandemics. Lipid analysis is critical to monitor the formulation process and control the quality of LNPs. The present study is focused on the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Mousli, Yannick, Brachet, Mathilde, Chain, Jeanne Leblond, Ferey, Ludivine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389849/
https://www.ncbi.nlm.nih.gov/pubmed/36054945
http://dx.doi.org/10.1016/j.jpba.2022.115011
_version_ 1784770545177329664
author Mousli, Yannick
Brachet, Mathilde
Chain, Jeanne Leblond
Ferey, Ludivine
author_facet Mousli, Yannick
Brachet, Mathilde
Chain, Jeanne Leblond
Ferey, Ludivine
author_sort Mousli, Yannick
collection PubMed
description Lipid nanoparticles (LNPs) have shown great success as drug delivery systems, especially for mRNA vaccines, as those developed during the Covid-19 pandemics. Lipid analysis is critical to monitor the formulation process and control the quality of LNPs. The present study is focused on the development and validation of a high-performance liquid chromatography – diode array detector –evaporative light scattering detector (HPLC-DAD/ELSD) based method for the simultaneous quantification of 7 lipids, illustrating the main components of LNPs: ionizable lipids, the neutral co-lipid cholesterol, phospholipids, hydrophilic polymer-lipids for colloidal stability (e.g., a PEGylated lipid). In particular, this study focuses on two innovative synthetic lipids: a switchable cationic lipid (CSL3) which has demonstrated in vitro and in vivo siRNA transfection abilities, and the palmitic acid-grafted-poly(ethyloxazoline)(5000) (PolyEtOx), used as an alternative polymer to address allergic reactions attributed to PEGylated lipids. The HPLC separation was achieved on a Poroshell C18 column at 50 °C using a step gradient of a mobile phase composed of water/methanol mixtures with 0.1% (v/v) trifluoroacetic acid (TFA). This method was validated following ICH Q2(R1) & (R2) guidelines in terms of linearity (R² ≥ 0.997), precision (relative standard deviation on peak areas < 5% for intermediate repeatability), accuracy (recoveries between 92.9% and 108.5%), and sensitivity. Indeed, low detection and quantitation limits were determined (between 0.02 and 0.04 µg and between 0.04 and 0.10 µg, respectively). Due to its high selectivity, this method allowed the analysis of lipid degradation products produced through degradation studies in basic, acidic, and oxidative conditions. Moreover, the method was successfully applied to the analysis of several liposome formulations at two key steps of the development process. Consequently, the reported HPLC method offers fast, versatile, selective and quantitative analysis of lipids, essential for development optimization, chemical characterization, and stability testing of LNP formulations.
format Online
Article
Text
id pubmed-9389849
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-93898492022-08-19 A rapid and quantitative reversed-phase HPLC-DAD/ELSD method for lipids involved in nanoparticle formulations Mousli, Yannick Brachet, Mathilde Chain, Jeanne Leblond Ferey, Ludivine J Pharm Biomed Anal Article Lipid nanoparticles (LNPs) have shown great success as drug delivery systems, especially for mRNA vaccines, as those developed during the Covid-19 pandemics. Lipid analysis is critical to monitor the formulation process and control the quality of LNPs. The present study is focused on the development and validation of a high-performance liquid chromatography – diode array detector –evaporative light scattering detector (HPLC-DAD/ELSD) based method for the simultaneous quantification of 7 lipids, illustrating the main components of LNPs: ionizable lipids, the neutral co-lipid cholesterol, phospholipids, hydrophilic polymer-lipids for colloidal stability (e.g., a PEGylated lipid). In particular, this study focuses on two innovative synthetic lipids: a switchable cationic lipid (CSL3) which has demonstrated in vitro and in vivo siRNA transfection abilities, and the palmitic acid-grafted-poly(ethyloxazoline)(5000) (PolyEtOx), used as an alternative polymer to address allergic reactions attributed to PEGylated lipids. The HPLC separation was achieved on a Poroshell C18 column at 50 °C using a step gradient of a mobile phase composed of water/methanol mixtures with 0.1% (v/v) trifluoroacetic acid (TFA). This method was validated following ICH Q2(R1) & (R2) guidelines in terms of linearity (R² ≥ 0.997), precision (relative standard deviation on peak areas < 5% for intermediate repeatability), accuracy (recoveries between 92.9% and 108.5%), and sensitivity. Indeed, low detection and quantitation limits were determined (between 0.02 and 0.04 µg and between 0.04 and 0.10 µg, respectively). Due to its high selectivity, this method allowed the analysis of lipid degradation products produced through degradation studies in basic, acidic, and oxidative conditions. Moreover, the method was successfully applied to the analysis of several liposome formulations at two key steps of the development process. Consequently, the reported HPLC method offers fast, versatile, selective and quantitative analysis of lipids, essential for development optimization, chemical characterization, and stability testing of LNP formulations. Elsevier B.V. 2022-10-25 2022-08-19 /pmc/articles/PMC9389849/ /pubmed/36054945 http://dx.doi.org/10.1016/j.jpba.2022.115011 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mousli, Yannick
Brachet, Mathilde
Chain, Jeanne Leblond
Ferey, Ludivine
A rapid and quantitative reversed-phase HPLC-DAD/ELSD method for lipids involved in nanoparticle formulations
title A rapid and quantitative reversed-phase HPLC-DAD/ELSD method for lipids involved in nanoparticle formulations
title_full A rapid and quantitative reversed-phase HPLC-DAD/ELSD method for lipids involved in nanoparticle formulations
title_fullStr A rapid and quantitative reversed-phase HPLC-DAD/ELSD method for lipids involved in nanoparticle formulations
title_full_unstemmed A rapid and quantitative reversed-phase HPLC-DAD/ELSD method for lipids involved in nanoparticle formulations
title_short A rapid and quantitative reversed-phase HPLC-DAD/ELSD method for lipids involved in nanoparticle formulations
title_sort rapid and quantitative reversed-phase hplc-dad/elsd method for lipids involved in nanoparticle formulations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389849/
https://www.ncbi.nlm.nih.gov/pubmed/36054945
http://dx.doi.org/10.1016/j.jpba.2022.115011
work_keys_str_mv AT mousliyannick arapidandquantitativereversedphasehplcdadelsdmethodforlipidsinvolvedinnanoparticleformulations
AT brachetmathilde arapidandquantitativereversedphasehplcdadelsdmethodforlipidsinvolvedinnanoparticleformulations
AT chainjeanneleblond arapidandquantitativereversedphasehplcdadelsdmethodforlipidsinvolvedinnanoparticleformulations
AT fereyludivine arapidandquantitativereversedphasehplcdadelsdmethodforlipidsinvolvedinnanoparticleformulations
AT mousliyannick rapidandquantitativereversedphasehplcdadelsdmethodforlipidsinvolvedinnanoparticleformulations
AT brachetmathilde rapidandquantitativereversedphasehplcdadelsdmethodforlipidsinvolvedinnanoparticleformulations
AT chainjeanneleblond rapidandquantitativereversedphasehplcdadelsdmethodforlipidsinvolvedinnanoparticleformulations
AT fereyludivine rapidandquantitativereversedphasehplcdadelsdmethodforlipidsinvolvedinnanoparticleformulations